U.S. Markets closed

Horizon Therapeutics Public Limited Company (HZNP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
108.52+0.72 (+0.67%)
At close: 04:00PM EDT
108.52 0.00 (0.00%)
After hours: 04:11PM EDT

Horizon Therapeutics Public Limited Company

70 St. Stephen’s Green
Dublin 2
353 1 772 2100

IndustryDrug Manufacturers—General
Full Time Employees2,095

Key Executives

NameTitlePayExercisedYear Born
Mr. Timothy P. WalbertChairman, Pres & CEO5.54M2.79M1967
Dr. Jeffrey W. Sherman F.A.C.P., FACP, M.D.Exec. VP & Chief Medical Officer1.65M5.89M1955
Mr. Paul W. HoelscherAdvisor2.07M806.39k1965
Mr. Andy PasternakExec. VP & Chief Strategy Officer1.67M3.74M1971
Mr. Aaron L. CoxExec. VP of Fin. & CFON/AN/A1983
Mr. Patrick McIlvennySr. VP & Chief Accounting OfficerN/AN/A1979
Ms. Tina E. VenturaSr. VP & Chief Investor Relations OfficerN/AN/AN/A
Mr. Sean M. Clayton J.D.Exec. VP & Gen. CounselN/AN/A1979
Mr. Geoffrey M. CurtisExec. VP of Corp. Affairs & Chief Communications OfficerN/AN/A1975
Ms. Jane GonnermanSr. VP of Corp. Devel. & Chief of Staff, Office of the CEON/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

Corporate Governance

Horizon Therapeutics Public Limited Company’s ISS Governance QualityScore as of February 1, 2023 is 2. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 5; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.